Talazoparib is a PARP inhibitor used for the treatment of specific tumors.During medication, close attention should be paid to myelosuppression, anemia, fatigue, and drug interactions to ensure efficacy and safety.

1.Myelosuppression

1.Risk manifestations

It can cause decreases in white blood cells, platelets, and red blood cells.

It increases the risk of infection, bleeding, and anemia.

2.Monitoring and management

Regular blood tests should be performed before and during treatment.

If fever, infection, or abnormal bleeding occurs, seek medical attention immediately.

In cases of severe myelosuppression, doctors may pause the medication, adjust the dose, or provide supportive treatment.

2.Anemia

1.Main symptoms

Common manifestations include fatigue, dizziness, pale complexion, and shortness of breath.

Severe cases can affect daily activities.

2.Coping measures

Regularly monitor hemoglobin levels.

Mild anemia can be managed through dietary supplementation of iron, folic acid, and vitamin B12.

Moderate to severe anemia requires medical evaluation, and blood transfusion or dose adjustment may be necessary.

3.Fatigue

1.Characteristics

Fatigue is a common adverse reaction and may be related to anemia, the drug itself, or the disease.

The degree varies among individuals and affects quality of life.

2.Management recommendations

Arrange rest reasonably and ensure adequate sleep.

Engage in moderate activity and avoid excessive fatigue.

Maintain a balanced diet and ensure adequate nutrition.

If fatigue is severe or continuously worsens, inform the doctor to investigate anemia or other causes.

4.Drug interactions

1.Main mechanism

Talazoparib is mainly metabolized by CYP3A4 and is also a P-glycoprotein substrate.

Co-administration with strong CYP3A4 inhibitors or inducers may alter drug exposure.

2.Common interactions

Strong CYP3A4 inhibitors (such as ketoconazole and clarithromycin) may increase talazoparib concentrations and increase toxicity.

Strong CYP3A4 inducers (such as rifampin and phenytoin) may reduce efficacy.

P-glycoprotein inhibitors may affect drug distribution.

3.Medication recommendations

Inform the doctor of all medications being used before treatment, including prescription drugs, over-the-counter drugs, and herbal medicines.

Avoid combining strong CYP3A4 inhibitors or inducers on your own.

If concomitant use is necessary, the doctor may adjust the dose and strengthen monitoring.